<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01005251</url>
  </required_header>
  <id_info>
    <org_study_id>D9120C00019</org_study_id>
    <nct_id>NCT01005251</nct_id>
  </id_info>
  <brief_title>Investigate the Effect of Different Doses of Lesogaberan (AZD3355) as add-on to PPI in GERD Patients With Partial Response to PPI</brief_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      This study is being carried out to see whether AZD3355 is an effective treatment as an add-on
      to PPI therapy in patients with Gastroesophageal Reflux Disease (GERD) with a partial
      response to PPI and to compare this with Proton Pump Inhibitor (PPI) treatment alone. Another
      goal of the study is to examine which of the investigated doses of AZD3355 is optimal for
      treatment of these patients. This study will also measure levels of drug in the blood and see
      how well it is tolerated.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2009</start_date>
  <completion_date type="Actual">July 2010</completion_date>
  <primary_completion_date type="Actual">July 2010</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment (Approximately 4 Weeks) Than During Baseline (the 7 Days Before Randomisation)</measure>
    <time_frame>The 7 days before randomisation (baseline) and during 26-30 days of treatment</time_frame>
    <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary.
(GERD = Gastroesophageal Reflux Disease)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Absolute Change From Baseline to Treatment Period in Percent Days With at Most Mild GERD Symptoms.</measure>
    <time_frame>The 7 days before randomisation (baseline) and during 26-30 days of treatment</time_frame>
    <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary
(GERD = Gastroesophageal Reflux Disease)</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">661</enrollment>
  <condition>Gastroesophageal Reflux Disease</condition>
  <condition>Heartburn</condition>
  <condition>Regurgitation</condition>
  <arm_group>
    <arm_group_label>60 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPI+lesogaberan (AZD3355) 60 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>120 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPI+lesogaberan (AZD3355) 120 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>180 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPI+lesogaberan (AZD3355) 180 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>240 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PPI+lesogaberan (AZD3355) 240 mg bid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>PPI+ Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesogaberan (AZD3355)</intervention_name>
    <description>60 mg, oral, capsules, bid for 4 w</description>
    <arm_group_label>60 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesogaberan (AZD3355)</intervention_name>
    <description>120 mg, oral, capsules, bid for 4 w</description>
    <arm_group_label>120 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesogaberan (AZD3355)</intervention_name>
    <description>180 mg, oral, capsules, bid for 4 w</description>
    <arm_group_label>180 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>lesogaberan (AZD3355)</intervention_name>
    <description>240 mg, oral, capsules, bid for 4 w</description>
    <arm_group_label>240 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>oral,capsules, bid for 4 w</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of informed consent prior to any study specific procedures

          -  Have at least 6 months history of GERD

          -  Continuously treated during the last 4 weeks before enrolment with daily optimized
             unchanged PPI therapy for any GERD indication

        Exclusion Criteria:

          -  Patients that have not experienced any GERD symptom improvement at all during PPI
             treatment

          -  Prior surgery of the upper gastrointestinal tract.

          -  Subject who have any of the following conditions or diseases: Heart disease, Angina,
             Seizure disorders such as epilepsy, Congestive Heart Failure (CHF), Liver disease such
             as Cirrhosis or Hepatitis, Kidney disease, Lung disease or lung cancer, Cancer
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debra Silberg, MD</last_name>
    <role>Study Director</role>
    <affiliation>AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Nicholas Shaheen, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>UNC Hospitals, 4141Chapel Hill, NC 27599 USA</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 27, 2009</study_first_submitted>
  <study_first_submitted_qc>October 29, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 30, 2009</study_first_posted>
  <results_first_submitted>February 23, 2011</results_first_submitted>
  <results_first_submitted_qc>March 29, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 25, 2011</results_first_posted>
  <last_update_submitted>March 29, 2011</last_update_submitted>
  <last_update_submitted_qc>March 29, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 25, 2011</last_update_posted>
  <responsible_party>
    <name_title>MSD</name_title>
    <organization>AstraZeneca</organization>
  </responsible_party>
  <keyword>GERD treatment</keyword>
  <keyword>Acid and non-acid Reflux</keyword>
  <keyword>Heartburn</keyword>
  <keyword>Regurgitation</keyword>
  <keyword>Add-on treatment to PPI</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroesophageal Reflux</mesh_term>
    <mesh_term>Heartburn</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lesogaberan</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>AZD3355 60 mg</title>
          <description>PPI+AZD3355 60 mg twice daily (bid)</description>
        </group>
        <group group_id="P2">
          <title>AZD3355 120 mg</title>
          <description>PPI+AZD3355 120 mg twice daily (bid)</description>
        </group>
        <group group_id="P3">
          <title>AZD3355 180 mg</title>
          <description>PPI+AZD3355 180 mg twice daily (bid)</description>
        </group>
        <group group_id="P4">
          <title>AZD3355 240 mg</title>
          <description>PPI+AZD3355 240 mg twice daily (bid)</description>
        </group>
        <group group_id="P5">
          <title>Placebo</title>
          <description>PPI+Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="125"/>
                <participants group_id="P3" count="136"/>
                <participants group_id="P4" count="126"/>
                <participants group_id="P5" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="121"/>
                <participants group_id="P2" count="109"/>
                <participants group_id="P3" count="114"/>
                <participants group_id="P4" count="114"/>
                <participants group_id="P5" count="122"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="16"/>
                <participants group_id="P3" count="22"/>
                <participants group_id="P4" count="12"/>
                <participants group_id="P5" count="18"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="4"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Eligibility criteria not fulfilled</title>
              <participants_list>
                <participants group_id="P1" count="4"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="4"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="6"/>
                <participants group_id="P3" count="8"/>
                <participants group_id="P4" count="5"/>
                <participants group_id="P5" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Developed study-specific withdrawal crit</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="3"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="2"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Patient moved</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Wrong drug dispensed</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Randomized in error</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>AZD3355 60 mg</title>
          <description>PPI+AZD3355 60 mg twice daily (bid)</description>
        </group>
        <group group_id="B2">
          <title>AZD3355 120 mg</title>
          <description>PPI+AZD3355 120 mg twice daily (bid)</description>
        </group>
        <group group_id="B3">
          <title>AZD3355 180 mg</title>
          <description>PPI+AZD3355 180 mg twice daily (bid)</description>
        </group>
        <group group_id="B4">
          <title>AZD3355 240 mg</title>
          <description>PPI+AZD3355 240 mg twice daily (bid)</description>
        </group>
        <group group_id="B5">
          <title>Placebo</title>
          <description>PPI+Placebo</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="134"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="136"/>
            <count group_id="B4" value="126"/>
            <count group_id="B5" value="140"/>
            <count group_id="B6" value="661"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.4" spread="12.3"/>
                    <measurement group_id="B2" value="46.1" spread="13.5"/>
                    <measurement group_id="B3" value="48.0" spread="12.3"/>
                    <measurement group_id="B4" value="48.5" spread="12.1"/>
                    <measurement group_id="B5" value="48.3" spread="12.0"/>
                    <measurement group_id="B6" value="47.7" spread="12.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="84"/>
                    <measurement group_id="B2" value="75"/>
                    <measurement group_id="B3" value="75"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="67"/>
                    <measurement group_id="B6" value="376"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="61"/>
                    <measurement group_id="B4" value="51"/>
                    <measurement group_id="B5" value="73"/>
                    <measurement group_id="B6" value="285"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment (Approximately 4 Weeks) Than During Baseline (the 7 Days Before Randomisation)</title>
        <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary.
(GERD = Gastroesophageal Reflux Disease)</description>
        <time_frame>The 7 days before randomisation (baseline) and during 26-30 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3355 60 mg</title>
            <description>PPI+AZD3355 60 mg twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>AZD3355 120 mg</title>
            <description>PPI+AZD3355 120 mg twice daily (bid)</description>
          </group>
          <group group_id="O3">
            <title>AZD3355 180 mg</title>
            <description>PPI+AZD3355 180 mg twice daily (bid)</description>
          </group>
          <group group_id="O4">
            <title>AZD3355 240 mg</title>
            <description>PPI+AZD3355 240 mg twice daily (bid)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>PPI+Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With a Change in GERD Symptoms Corresponding to at Least Three More Days of Not More Than Mild Symptoms on Average Per Week During Treatment (Approximately 4 Weeks) Than During Baseline (the 7 Days Before Randomisation)</title>
          <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary.
(GERD = Gastroesophageal Reflux Disease)</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="134"/>
                <count group_id="O2" value="125"/>
                <count group_id="O3" value="136"/>
                <count group_id="O4" value="126"/>
                <count group_id="O5" value="140"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28"/>
                    <measurement group_id="O2" value="32"/>
                    <measurement group_id="O3" value="32"/>
                    <measurement group_id="O4" value="33"/>
                    <measurement group_id="O5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Absolute Change From Baseline to Treatment Period in Percent Days With at Most Mild GERD Symptoms.</title>
        <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary
(GERD = Gastroesophageal Reflux Disease)</description>
        <time_frame>The 7 days before randomisation (baseline) and during 26-30 days of treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>AZD3355 60 mg</title>
            <description>PPI+AZD3355 60 mg twice daily (bid)</description>
          </group>
          <group group_id="O2">
            <title>AZD3355 120 mg</title>
            <description>PPI+AZD3355 120 mg twice daily (bid)</description>
          </group>
          <group group_id="O3">
            <title>AZD3355 180 mg</title>
            <description>PPI+AZD3355 180 mg twice daily (bid)</description>
          </group>
          <group group_id="O4">
            <title>AZD3355 240 mg</title>
            <description>PPI+AZD3355 240 mg twice daily (bid)</description>
          </group>
          <group group_id="O5">
            <title>Placebo</title>
            <description>PPI+Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Absolute Change From Baseline to Treatment Period in Percent Days With at Most Mild GERD Symptoms.</title>
          <description>Symptom intensity rated by participants twice daily on a six-graded Likert scale (Did not have; Very mild; Mild; Moderate; Moderately severe; Severe) using an electronic Reflux Symptom Questionnaire diary
(GERD = Gastroesophageal Reflux Disease)</description>
          <units>Percent</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="132"/>
                <count group_id="O2" value="117"/>
                <count group_id="O3" value="133"/>
                <count group_id="O4" value="123"/>
                <count group_id="O5" value="135"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.7" lower_limit="0" upper_limit="35.7"/>
                    <measurement group_id="O2" value="17.2" lower_limit="0" upper_limit="46.4"/>
                    <measurement group_id="O3" value="11.9" lower_limit="0" upper_limit="40.9"/>
                    <measurement group_id="O4" value="12.5" lower_limit="0" upper_limit="47.1"/>
                    <measurement group_id="O5" value="0" lower_limit="0" upper_limit="30.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <desc>As a consequence of the definition of the analysis set for efficacy analysis and safety analysis respectively, one patient was included in the 120 mg group for efficacy analyses and in the 60 mg group for safety analyses.</desc>
      <group_list>
        <group group_id="E1">
          <title>AZD3355 60 mg</title>
          <description>PPI+AZD3355 60 mg twice daily (bid)</description>
        </group>
        <group group_id="E2">
          <title>AZD3355 120 mg</title>
          <description>PPI+AZD3355 120 mg twice daily (bid)</description>
        </group>
        <group group_id="E3">
          <title>AZD3355 180 mg</title>
          <description>PPI+AZD3355 180 mg twice daily (bid)</description>
        </group>
        <group group_id="E4">
          <title>AZD3355 240 mg</title>
          <description>PPI+AZD3355 240 mg twice daily (bid)</description>
        </group>
        <group group_id="E5">
          <title>Placebo</title>
          <description>PPI+Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0"/>
                <counts group_id="E2" subjects_affected="0"/>
                <counts group_id="E3" subjects_affected="0"/>
                <counts group_id="E4" subjects_affected="1"/>
                <counts group_id="E5" subjects_affected="1"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Non-Cardiac Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Metastatic Gastric Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 13.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13"/>
                <counts group_id="E2" subjects_affected="12"/>
                <counts group_id="E3" subjects_affected="16"/>
                <counts group_id="E4" subjects_affected="20"/>
                <counts group_id="E5" subjects_affected="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Paraesthesia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="135"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="124"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="136"/>
                <counts group_id="E4" subjects_affected="11" subjects_at_risk="126"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="140"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is an agreement between PI and Sponsor (AZ) or its agents that restricts the PI's right to discuss/publish trial results after the trial is completed.The PI agrees to collaborate in good faith with AZ with regards to content and formation of any publication or disclosure to be made by PI and to pay due consideration to opinions offered by AZ.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Gerard Lynch</name_or_title>
      <organization>AstraZeneca</organization>
      <email>ClinicalTrialTransparency@astrazeneca.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

